CGEM — Cullinan Therapeutics Share News
0.000.00%
Last trade - 00:00- $960.17m
- $625.63m
Cullinan Therapeutics Inc expected to post a loss of 73 cents a share - Earnings Preview
Brief: Cullinan Therapeutics Files For Resale Of 14.4 Mln Shares By The Selling Stockholders
Cullinan Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Cullinan Oncology Q1 Adjusted Net Income USD -37.3 Million
Cullinan Therapeutics Inc expected to post a loss of 99 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-3M, J&J, Nuvalent
Cullinan Oncology Inc reports results for the quarter ended in December - Earnings Summary
Brief: Cullinan Oncology Reports Fourth Quarter And Full Year 2023 Results
Brief: Cullinan Oncology Q4 Adjusted Net Income USD -25.6 Million
U.S. STOCKS ON THE MOVE-Madrigal Pharma, Copper miners, NetApp
Cullinan Oncology rises as FDA clears blood cancer therapy for clinical trials
Brief: Cullinan Oncology Announces FDA Clearance Of Investigational New Drug Application For CLN-619, For Relapsed/Refractory Multiple Myeloma
Brief: Cullinan Oncology Announces First Patient Dosed In Phase 1 Trial Evaluating Cln-617, A Novel Fusion Protein Uniquely Harnessing Both Il-2 And Il-12 Cytokines
Brief: Cullinan Oncology Provides Corporate Update And Reports Third Quarter 2023 Financial Results
Brief: Cullinan Oncology Q3 Adjusted Net Income USD -39.2 Million
U.S. RESEARCH ROUNDUP-Elf Beauty, PTC Therapeutics, Shoals Technologies Group
Cullinan Oncology Inc reports results for the quarter ended in June - Earnings Summary
Brief: Cullinan Oncology Q2 Adjusted Net Income USD -32.2 Million
Cullinan Oncology Inc expected to post a loss of 97 cents a share - Earnings Preview